apremilast(redirected from Otezla)
Pregnancy Category: C
Pharmacologic: temporary class
Pharmacologic: temporary class
Treatment of active psoriatic arthritis.
Acts as an inhibitor of phosphodiesterase type 4 (PDE4). Inhibition of PDE4 results in ↑ intracellular levels of cyclic adenosine monophosphate (cAMP).
Decreased severity of psoriatic arthritis with improved joint function.
Absorption: 73 % absorbed following oral administration.
Metabolism and Excretion: Extensively metabolized (mostly by CYP3A4); metabolites are not pharmacologically active. Excreted in urine (58%) and feces (39%) as inactive metabolites; 3% excreted unchanged in urine, 7% in feces.
Half-life: 6–9 hr.
Time/action profile (blood levels†)
|PO||unknown||2.5 hr||12–24 hr|
Contraindicated in: Hypersensitivity;Concurrent use of P450 enzyme inducers.
Use Cautiously in: History of depression or suicidal ideation; Severe renal impairment (dose reduction required for CCr <30 mL/min); Obstetric: Use during pregnancy only if potential benefits justify potential fetal risks; Lactation: Use caution if breastfeeding; Pediatric: Safe and effective use in children <18 yr has not been established.
Adverse Reactions/Side Effects
Central nervous system
- upper abdominal pain
- weight loss
Drug-Drug interactionConcurrent use of P450 enzyme inducers including carbamazepine, phenobarbital, phenytoin and rifampin may ↓ blood levels and effectiveness; concurrent use should be avoided.
Oral (Adults ) Day 1—10 mg in the morning; day 2—10 mg in the morning and 10 mg in the evening; day 3—10 mg in the morning and 20 mg in the evening; day 4—20 mg in the morning and 20 mg in the evening; day 5—20 mg in the morning and 30 mg in the evening; day 6 and thereafter—30 mg in the morning and 30 mg in the evening.
Renal ImpairmentOral (Adults CCr <30 mL/min) Days 1–3—10 in the morning; days 4–5—20 mg in the morning; day 6 and thereafter—30 mg in the morning.
Tablets: 10 mg, 20 mg, 30 mg
- Assess pain and range of motion before and periodically during therapy.
- Monitor mental status for signs and symptoms of depression (orientation, mood behavior) frequently. Assess for suicidal tendencies, especially during early therapy.
- Obtain weight and BMI initially and periodically during treatment. If clinically significant weight loss occurs, evaluate weight loss and consider discontinuation of therapy.
Potential Nursing DiagnosesChronic pain (Indications)
Impaired skin integrity (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)
- Follow titration guidelines when beginning therapy to minimize GI side effects.
- Oral: Administer without regard for meals. Swallow tablet whole; do not crush, break, or chew.
- Instruct patient to take apremilast as directed.
- Advise patient, family and caregivers to look for suicidality, especially during early therapy or dose changes. Notify health care professional immediately if thoughts about suicide or dying, attempts to commit suicide, new or worse depression or anxiety, agitation or restlessness, panic attacks, insomnia, new or worse irritability, aggressiveness, acting on dangerous impulses, mania, or other changes in mood or behavior occur.
- Inform patient of need to monitor weight regularly. Notify health care professional if unexplained or clinically significant weight loss occurs.
- Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
- Improvement in pain and function in patients with psoriatic arthritis.
Drug Guide, © 2015 Farlex and Partners